Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.74 |
| ▸ | DRD3 | P35462 | 3/20 | 0.74 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | PLAU | P00749 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 3/20 | 0.51 |
| ▸ | HTR7 | P34969 | 3/20 | 0.51 |
| ▸ | HTR1D | P28221 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HTR1B | P28222 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL265580 | 0.85 | DRD2 (1.00) | DRD2DRD3PLAUNFKB1THPO | |
| SCHEMBL3318587 | 0.85 | DRD2 (1.00) | DRD2DRD3PLAUNFKB1THPO | |
| SCHEMBL31681697 | 0.85 | DRD2 (1.00) | DRD2DRD3PLAUNFKB1THPO | |
| SCHEMBL11981410 | 0.85 | DRD2 (1.00) | DRD2DRD3PLAUNFKB1THPO | |
| Bromide SCHEMBL10358294 | 0.84 | DRD2 (0.96) | DRD2DRD3PLAUNFKB1THPO | |
| SCHEMBL4813078 | 0.79 | CHRM3 (0.65) | DRD2DRD3CHRM3CHRM2CHRM1 | |
| SCHEMBL8822636 | 0.78 | PLAU (0.55) | DRD2DRD3PLAUNFKB1THPO | |
| SCHEMBL3760340 | 0.78 | PLAU (0.55) | DRD2DRD3PLAUCYP2D6ADRA1A | |
| SCHEMBL22061859 | 0.78 | DRD2 (0.74) | DRD2DRD3PLAUADRA1A | |
| SCHEMBL14591309 | 0.78 | PLAU (0.55) | DRD2DRD3PLAUADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11198685-B2 | Substituted ureas and methods of making and using same | MEBIAS DISCOVERY, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20200308155-A1 | Substituted Ureas and Methods of Making and Using Same | MEBIAS DISCOVERY, INC. | 2020-10-01 | — | — | US | disclosed |
| US-10683283-B2 | Substituted ureas and methods of making and using same | MEBIAS DISCOVERY, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-8431378-B2 | Aminotransferase, gene encoding the same, and methods of using them | KANEKA CORPORATION (JP) | 2013-04-30 | — | — | US | disclosed |
| US-20120270875-A1 | PYRIMIDINE AMIDE COMPOUNDS | GILLESPIE PAUL (US) | 2012-10-25 | — | — | US | disclosed |
| WO-2012123467-A1 | PYRIMIDINE AMIDE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | WO | disclosed |
| US-8227604-B2 | Hybrid 2-aminotetralin and aryl-substituted piperazine compounds and their use in altering CNS activity | WAYNE STATE UNIVERSITY (US) | 2012-07-24 | — | — | US | disclosed |
| US-20120164724-A1 | NOVEL AMINOTRANSFERASE, GENE ENCODING THE SAME, AND METHODS OF USING THEM | KANEKA CORPORATION (JP) | 2012-06-28 | — | — | US | disclosed |
| US-8133705-B2 | Aminotransferase, gene encoding the same, and method of using them | KANEKA CORPORATION (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20100285544-A1 | Novel aminotransferase, gene encoding the same, and method of using them | KANEKA CORPORATION (JP) | 2010-11-11 | — | — | US | disclosed |
| US-20100210663-A1 | Hybrid 2-Aminotetralin and Aryl-Substituted Piperazine Compounds and their Use in Altering CNS Activity | WAYNE STATE UNIVERSITY (US) | 2010-08-19 | — | — | US | disclosed |
| US-7723519-B2 | Hybrid 2-aminoterailin and aryl-substituted piperazine compounds and their use in altering CNS activity | WAYNE STATE UNIVERSITY (US) | 2010-05-25 | — | — | US | disclosed |
| EP-1889907-B1 | NOVEL AMINO GROUP TRANSFERASE, GENE ENCODING THE SAME AND METHOD OF USING THE SAME | KANEKA CORP (JP) | 2009-09-02 | — | — | EP | disclosed |
| EP-1889907-A1 | NOVEL AMINO GROUP TRANSFERASE, GENE ENCODING THE SAME AND METHOD OF USING THE SAME | Kaneka Corporation (JP) | 2008-02-20 | — | — | EP | disclosed |
| US-20060020132-A1 | Hybrid 2-aminoterailin and aryl-substituted piperazine compounds and their use in altering CNS activity | WAYNE STATE UNIVERSITY (US) | 2006-01-26 | — | — | US | disclosed |
| US-6982332-B2 | Hybrid 2-aminotetralin and aryl-substituted piperazine compounds and their use in altering CNS activity | WAYNE STATE UNIVERSITY (US) | 2006-01-03 | — | — | US | disclosed |
| US-20030195219-A1 | Hybrid 2-aminotetralin and aryl-substituted piperazine compounds and their use in altering cns activity | WAYNE STATE UNIVERSITY | 2003-10-16 | — | — | US | disclosed |
| WO-2002098367-A2 | HYBRID 2-AMINOTETRALIN AND ARYL-SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE IN ALTERING CNS ACTIVITY | WAYNE STATE UNIVERSITY (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195219-A1 | Hybrid 2-aminotetralin and aryl-substituted piperazine compounds and their use in altering cns activity | HTR3A, HTR3C, HTR2C | DRD2 5/4885DRD3 7/4885CHRM3 97/4885 |
| US-20120270875-A1 | PYRIMIDINE AMIDE COMPOUNDS | UMPS, TYMS, DPYD | DRD2 3415/4885DRD3 4074/4885CHRM3 497/4885 |
| US-20100210663-A1 | Hybrid 2-Aminotetralin and Aryl-Substituted Piperazine Compounds and their Use in Altering CNS Activity | HTR3A, HTR3C, HTR2C | DRD2 5/4885DRD3 7/4885CHRM3 96/4885 |
| US-10683283-B2 | Substituted ureas and methods of making and using same | UMPS, METTL3, UTS2R | DRD2 3348/4885DRD3 2618/4885CHRM3 1670/4885 |
| US-11198685-B2 | Substituted ureas and methods of making and using same | UMPS, METTL3, UTS2R | DRD2 3348/4885DRD3 2618/4885CHRM3 1670/4885 |
| US-20060020132-A1 | Hybrid 2-aminoterailin and aryl-substituted piperazine compounds and their use in altering CNS activity | HTR3A, DRD3, DRD2 | DRD2 3/4885DRD3 2/4885CHRM3 66/4885 |
| US-20200308155-A1 | Substituted Ureas and Methods of Making and Using Same | UMPS, METTL3, UTS2R | DRD2 3348/4885DRD3 2618/4885CHRM3 1670/4885 |
| US-20100285544-A1 | Novel aminotransferase, gene encoding the same, and method of using them | BCAT1, AGXT, ALDH7A1 | DRD2 4646/4885DRD3 4278/4885CHRM3 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.